Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.7
16.49
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc
Cash Taxes Paid
Zentalis Pharmaceuticals Inc
Cash Taxes Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Taxes Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
|
Cash Taxes Paid
$140k
|
CAGR 3-Years
91%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash Taxes Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash Taxes Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash Taxes Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash Taxes Paid
$1.6B
|
CAGR 3-Years
47%
|
CAGR 5-Years
129%
|
CAGR 10-Years
84%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash Taxes Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Zentalis Pharmaceuticals Inc
Glance View
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. The company is headquartered in New York City, New York and currently employs 177 full-time employees. The company went IPO on 2020-04-03. The company is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidates, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors. Its other products include ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of non-Hodgkin’s lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.
See Also
What is Zentalis Pharmaceuticals Inc's Cash Taxes Paid?
Cash Taxes Paid
140k
USD
Based on the financial report for Dec 31, 2023, Zentalis Pharmaceuticals Inc's Cash Taxes Paid amounts to 140k USD.
What is Zentalis Pharmaceuticals Inc's Cash Taxes Paid growth rate?
Cash Taxes Paid CAGR 3Y
91%
Over the last year, the Cash Taxes Paid growth was 1 300%. The average annual Cash Taxes Paid growth rates for Zentalis Pharmaceuticals Inc have been 91% over the past three years .
You don't have any saved screeners yet
